| 赵斐斐,牛银花,斯琴塔娜,张 姝,高 伟.脑益嗪、非那根联合治疗耳石症疗效及复发率影响[J].,2020,(19):3723-3726 |
| 脑益嗪、非那根联合治疗耳石症疗效及复发率影响 |
| Efficacy and Recurrence Rate of Cerebral Irazine and Finagan in the Treatment of Otolith |
| 投稿时间：2020-01-31 修订日期：2020-02-26 |
| DOI：10.13241/j.cnki.pmb.2020.19.026 |
| 中文关键词: 脑益嗪 非那根 耳石症 联合治疗 复发率 |
| 英文关键词: Ceramexazine Finagen Otolith Combination therapy Relapse rate |
| 基金项目:内蒙古自治区自然科学基金项目（2017MS08108） |
|
| 摘要点击次数: 685 |
| 全文下载次数: 441 |
| 中文摘要: |
| 摘要 目的：探究耳石症应用脑益嗪与非那根联合治疗的有效性，并就联合治疗对复发率影响进行分析。方法：选择2018年1月至2019年1月于我院接受治疗的98例耳石症患者，按照随机数字表法将其均分为研究组与对照组（每组各49例），对照组单纯接受非那根治疗，研究组在对照组基础上加用脑益嗪进行治疗，两组治疗时间均为4 w，对比两组治疗有效率，对比治疗前、治疗第2 w研究组及治疗第4 w时两组的眩晕评定量表（Dizziness Handicap Inventory，DHI）评分，对比两组治疗后1 w平均眩晕次数及平均眩晕时间，最后对两组实施为期3个月的随访，记录其耳石症复发率并进行对比。结果：（1）研究组治疗有效率显著高于对照组（97.96 % vs. 81.63 %，P<0.05）；（2）治疗前两组DHI评分对比差异不具有统计学意义（P>0.05），治疗后第2 w及第4 w研究组DHI评分均低于对照组（P<0.05）；（3）治疗后1 w内研究组平均眩晕次数及平均眩晕时间均低于对照组（P<0.05）；（4）随访显示研究组治疗后3个月内复发率显著低于对照组（4.08 % vs. 16.33 %，P<0.05）。结论：脑益嗪联合非那根对耳石症具有较好的治疗效果，能够显著改善患者眩晕症状，同时治疗后复发率更低。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effectiveness of combined treatment with cerebrolysin and phenagen in otolithiasis, and to analyze the effect of combined therapy on relapse rate. Methods: 98 patients with otolithosis who were treated in our hospital from January 2018 to January 2019 were selected as the research subjects, and they were divided into study group and control group according to the random number table method (49 patients in each group), The patients in the control group received finagan alone, and the patients in the study group were treated with cerebrazine on the basis of the control group. The treatment time in two groups was 4 weeks. The treatment efficiency was compared between the two groups. The Dizziness Rating Scale (DHI) scores of the two groups at the 2 w and the 4 w of the treatment were compared with the average number of vertigo and the average time of vertigo within 1 w after treatment. Follow-up, record the rate of otolith recurrence and compare. Results: (1) The effective rate of treatment in the study group was statistically significant than in the control group (97.96 % vs. 81.63 %, P<0.05). (2) Comparison of the DHI scores between the two groups of patients pretherapy, the difference was not statistically significant(P>0.05). The DHI scores of the study group were lower than those of the control group at 2 and 4 w post-treatment(P<0.05). (3) The average number of vertigo and the average vertigo time in the study group were lower than those in the control group within 1 w pretherapy(P<0.05). (4) Follow-up showed that the relapse rate in the study group was significantly lower than that in the control group within 3 months post-treatment (4.08 % vs. 16.33 %, P<0.05). Conclusion: Ceramazine combined with finnagan has a good therapeutic effect on otolith, which can significantly improve the symptoms of vertigo in patients with lower recurrence rate post-treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
